Products from TargetMol
TargetMol, based in Boston, Massachusetts, was founded in 2015 and is a drug screening expert in the life science community. The company offers diverse compound libraries, including FDA-approved libraries, and covers a broad spectrum of small molecule compounds such as inhibitors and agonists as well as recombinant proteins and natural products. TargetMol's products are used by researchers worldwide in areas such as cancer research, neurobiology, inflammation, immunology and metabolism.
More information at: www.targetmol.com
No results were found for the filter!
NEW
Lilotomab
Item number: TGM-T77066-10mg
Description: Lilotomab (HH1) is a murine anti-CD37 antibody with anti-tumor activity. It can be used as a synthetic anti-CD37 antibody-radionuclide coupling (177Lu-lilotomab satetraxetan). Target: Apoptosis. References: Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to...
| Keywords: | HH1 |
From 248.00€
*
NEW
Lonigutamab
Item number: TGM-T77071-10mg
Description: Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the study of thyroid eye disease. Target: ADC Antibody, IGF-1R. References: Akla B, et al. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor...
| Keywords: | VB421 , hz208F2-4 , VB-421 |
From 186.00€
*
NEW
Losatuxizumab
Item number: TGM-T77073-10mg
Description: Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors. Target: EGFR. References: Reilly EB, et al. Characterization of ABT-806, a Humanized...
| Keywords: | ABT806 , ABT-806 |
From 186.00€
*
NEW
Lulizumab pegol
Item number: TGM-T77074-10mg
Description: Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist that inhibits T-cell proliferation, offering potential therapeutic applications for kidney transplantation and autoimmune disease research [1].
From 375.00€
*
NEW
Maftivimab
Item number: TGM-T77078-10mg
Description: Maftivimab (REGN3470-3471-3479), also known as Atoltivimab, Odesivimab (Inmazeb), is a Filovirus inhibitor and a Food and Drug Administration (FDA)-approved agent for the research of Zaire ebolavirus infection [1]. Target: Virus Protease
From 233.00€
*
NEW
Melrilimab
Item number: TGM-T77083-10mg
Description: Melrilimab (GSK 3772847) is an IgG antibody targeting IL-33R with high affinity for IL1RL1/ST2/DER4/FIT-1 and can be used in asthma research. Target: Interleukin. References: Salvati L, et al. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma. Curr Opin Allergy Clin...
| Keywords: | CNTO7160 , GSK 3772847 , CNTO-7160 , GSK3772847 |
From 186.00€
*
NEW
Navivumab
Item number: TGM-T77094-10mg
Description: Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1]. Target: Influenza Virus
From 233.00€
*
NEW
Nemvaleukin alfa
Item number: TGM-T77096-10mg
Description: Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor...
| Keywords: | Nemva , RDB-1450 , ALKS4230 , ALKS 4230 , RDB1450 |
From 390.00€
*
NEW
Nurulimab
Item number: TGM-T77103-10mg
Description: Nurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases. Target: Immunology/Inflammation related, Others. References: International Nonproprietary Names for Pharmaceutical Substances...
| Keywords: | BCD-145 , BCD145 |
From 186.00€
*
NEW
Obrindatamab
Item number: TGM-T77104-10mg
Description: Obrindatamab, a humanized anti-B7-H3/CD3 bispecific antibody, targets B7-H3 and CD3, facilitating redirected cytotoxic T-lymphocyte (CTL) activity towards B7-H3-expressing cancer cells. It is utilized in cancer research [1]. Target: Integrin
From 510.00€
*
NEW
Plamotamab
Item number: TGM-T77115-10mg
Description: Plamotamab (XmAb-13676), a human bispecific antibody (bsAb) targeting CD3 and CD20, recruits cytotoxic T cells to eliminate CD20-expressing tumor cells. It demonstrates mild hematologic reaction (MR) and effectively induces tumor regression in vivo [1] [2]. Target: Integrin, Immunology/Inflammation...
From 627.00€
*
NEW
Orticumab
Item number: TGM-T77123-10mg
Description: Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also...
| Keywords: | MLDL1278A |
From 390.00€
*